Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19718306 | 0.84 | TSHR (0.62) | LMNATSHRSLC15A2KDM4EKDM6B | |
| SCHEMBL11529618 | 0.83 | ALDH1A1 (0.56) | LMNATSHRALDH1A1SLC15A2KDM4E | |
| SCHEMBL16526493 | 0.82 | LMNA (0.41) | LMNATSHRALDH1A1SLC15A2 | |
| SCHEMBL9889745 | 0.82 | LMNA (0.38) | LMNATSHRALDH1A1 | |
| SCHEMBL9889748 | 0.81 | LMNA (0.35) | LMNAALDH1A1 | |
| SCHEMBL26210094 | 0.80 | LMNA (0.46) | LMNATSHRKDM4AKDM4C | |
| SCHEMBL15344335 | 0.79 | FAAH (0.39) | LMNATSHRALDH1A1PAOX | |
| SCHEMBL26210832 | 0.78 | LMNA (0.45) | LMNATSHRALDH1A1KDM4AKDM4C | |
| SCHEMBL20630575 | 0.78 | TSHR (0.48) | LMNATSHRALDH1A1KDM4AKDM4C | |
| SCHEMBL14878514 | 0.78 | LMNA (0.46) | LMNATSHRALDH1A1KDM4EKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164003-A2 | REAGENTS FOR LABELING BIOMOLECULES AND USES THEREOF | ULTIMA GENOMICS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-3564252-A1 | MODIFIED NUCLEOTIDE LINKERS | Illumina Cambridge Limited (GB) | 2019-11-06 | — | — | EP | disclosed |
| WO-2019023501-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-9498518-B2 | Targeting of glycoprotein therapeutics | GENZYME CORPORATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160040225-A1 | MODIFIED NUCLEOTIDE LINKERS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20150320844-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | GENZYME CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-8906379-B2 | Targeting of glycoprotein therapeutics | GENZYME CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906379-B2 | Targeting of glycoprotein therapeutics | GENZYME CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| US-20120141507-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | GENZYME CORPORATION | 2012-06-07 | — | — | US | disclosed |
| US-7341720-B2 | Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc.; treatment of lysosomal storage disorders | GENZYME CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160040225-A1 | MODIFIED NUCLEOTIDE LINKERS | RNGTT, DTYMK, DPYD | LMNA 639/4885TSHR 4204/4885ALDH1A1 2102/4885 |
| US-20150320844-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | SIGLEC7, LAMP2, ASGR1 | LMNA 2289/4885TSHR 1391/4885ALDH1A1 2570/4885 |
| US-20120141507-A1 | TARGETING OF GLYCOPROTEIN THERAPEUTICS | SIGLEC7, LAMP2, ASGR1 | LMNA 2289/4885TSHR 1391/4885ALDH1A1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.